ANN & ROBERT H. LURIE CHILDRENS HOS
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $46.5M
- Transactions
- 4,370
- Companies
- 40
- Average per transaction
- $10,645
Who reported the payments
| Vertex | $4,332,471 |
| Biogen | $4,204,228 |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,987,529 |
| Modernatx, Inc. | $3,862,389 |
| Biomarin Pharmaceutical Inc. | $2,832,588 |
| Sarepta Therapeutics, Inc. | $2,127,548 |
| Novartis | $1,962,018 |
| Pfizer | $1,711,342 |
| Shire North American Group Inc | $1,336,946 |
| AstraZeneca | $1,305,309 |
| Sanofi | $1,271,776 |
| Med-el Corporation | $1,199,284 |
| Merck | $1,060,733 |
| Ultragenyx Pharmaceutical Inc. | $988,689 |
| Gilead | $954,513 |
| AbbVie | $839,997 |
| Amgen | $659,942 |
| Jazz Pharmaceuticals Inc. | $572,243 |
| GW Research Limited | $543,561 |
| National Marrow Donor Program | $503,442 |
| Genetix Biotherapeutics Inc | $493,038 |
| Harmony Biosciences LLC | $492,351 |
| Regeneron | $468,755 |
| Bristol Myers Squibb | $461,475 |
| Acadia Pharmaceuticals Inc | $424,487 |
| Astrazeneca UK Limited | $378,592 |
| Abbott | $359,613 |
| Astellas Pharma Global Development | $353,857 |
| NS Pharma, Inc. | $353,005 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | $333,748 |
| Aimmune Therapeutics, Inc. | $330,613 |
| Rhythm Pharmaceuticals, Inc. | $279,645 |
| Kls-martin L.p. | $255,443 |
| Livanova USA, Inc. | $250,737 |
| GE HealthCare | $244,161 |
| E.r. Squibb & Sons, L.L.C. | $242,992 |
| Eli Lilly | $219,876 |
| Argenx US, Inc. | $212,521 |
| Sanofi US Services Inc. | $209,795 |
| Medtronic | $186,824 |